GLP-1RA in MASH – what’s new?

Metabolic dysfunction-associated steatohepatitis (MASH) corresponds to
the liver disease formerly known as non-alcoholic fatty liver inflammation (NASH). The most common causes of MASH are obesity and diabetes. There are still no specifically approved drugs in this country, which is why pharmacotherapy focuses on the accompanying metabolic diseases. The GLP-1RA semaglutide can contribute to a reduction in fibrosis in MASH, as current study findings show. Interesting data are also available on resmetirome and other active substances.